Dr. Bryan J. Schneider, MD

Dr. Schneider practices at University Hospital in Ann Arbor, Michigan.

Dr. Schneider's NPI, 1811073786, was assigned on October 31, 2006. Dr. Schneider graduated from Indiana University School of Medicine in 1998. Dr. Schneider holds Michigan license 4301079450.

Dr. Schneider's primary practice is University Hospital, at 1500 E Medical Center Dr, Ann Arbor, MI 48109. The practice phone is (734) 936-4000.

Dr. Schneider's primary practice is University Hospital in Ann Arbor, Michigan. Dr. Schneider is also affiliated with University Hospital. The medical group on file is University of Michigan Health. Dr. Schneider's employer is on file too: a school & student health.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Schneider practices, 2 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Schneider's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dmand AI has Dr. Schneider's licenses on file in 2 states: Michigan and New York.

CMS data shows 213 Medicare services from Dr. Schneider across 6 procedure codes in 2024, for 83 Medicare patients. Medicare paid $19,084 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 83 Medicare patients who saw Dr. Schneider in 2024. The largest group is 65 to 74, with 39 patients. 75% of them have high blood pressure, and 73% have high cholesterol. 16% are also on Medicaid. Their average risk score is 2.73, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Schneider's median patient age at 68, with 45% women.

In 2024, Dr. Schneider wrote 250 Medicare Part D claims for 64 patients. 64% of them were for generic drugs. CMS names the drug for 184 of them, across 8 drugs with 11 or more claims each, at $493,673 in total drug cost. In 2023, CMS named 119 claims across 7 drugs.

Dr. Schneider accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Schneider as offering telehealth.

Dmand AI links 67 papers to Dr. Schneider, published from 2007 to 2025. 2022 was the busiest year, with 9. The most frequent topics are Lung Neoplasms, Carcinoma, Non-Small-Cell Lung and Antineoplastic Combined Chemotherapy Protocols. Dr. Schneider has published most often in J Clin Oncol. Dr. Schneider's most frequent co-authors are Gregory A. Masters, MD, Gregory P. Kalemkerian, MD and Jarushka Naidoo, BAO, BCH, MB.

Dmand AI links Dr. Schneider to 10 clinical trials, 5 of them phase 2 studies. 4 are still active or recruiting. Conditions studied include Breast Neoplasms, Breast Diseases and Neoplasm Metastasis. National Cancer Institute (NCI) sponsors the most, 3.

CMS Open Payments shows 18 general payments to Dr. Schneider from 5 drug and device companies from 2016 to 2018. Consulting fees make up the largest share, 51% of the total. Genentech, Inc. paid the most, $7,969. It also lists 1 research payment totaling $8,801 in 2017.

Dr. Schneider graduated from Indiana University School of Medicine in 1998.